A highly anticipated cancer blood test, touted as a game-changer in medical research, has faced setbacks in its bid for NHS approval. The innovative Galleri test, designed to detect various cancers through blood analysis before symptoms manifest, underwent a rigorous three-year evaluation on over 142,000 NHS patients aged 50 to 77. Despite its ambitious goal of reducing late-stage cancer diagnoses, the trial, costing £150 million, fell short of expectations.
Although the primary objective of decreasing stage three and four cancer diagnoses was not met, there were positive outcomes noted. Notably, stage four cancer diagnoses saw a significant decrease, offset by a rise in stage three cases. GRAIL, the developer of the Galleri test, suggested that the shift from later to earlier stage diagnoses may have contributed to this increase.
The Galleri test, crafted by GRAIL in the United States, is a groundbreaking Multi-Cancer Early Detection (MCED) blood test capable of screening for over 50 cancer types from a single blood sample, often detecting cancers before symptoms emerge. Despite the mixed results, the potential of this test was recognized by former NHS chief executive Amanda Pritchard, who envisioned a transformative impact on cancer detection and treatment globally.
Presented at the American Society of Clinical Oncology’s annual conference in Chicago, the trial results prompted GRAIL’s chief medical officer, Julie Gralow, to acknowledge that further data would be needed for NHS approval. However, Professor Richard Houlston from The Institute of Cancer Research cautioned against downplaying the primary goal’s importance in light of positive indicators.
Looking ahead, Professor Peter Johnson, national clinical director for cancer at NHS England, emphasized the significance of early cancer detection in line with the National Cancer Plan. The NHS remains committed to exploring avenues for timely cancer detection to enhance patient outcomes. Further analysis of the trial data will guide future decisions regarding the potential integration of the Galleri test within the NHS framework.